Investigational drug · Phase 2
HLX53
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Carcinoma, Hepatocellular.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HLX53"
First trial start
2024
Aug 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX53", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Hepatocellular
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX53" as an intervention, largest first.
- A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Pivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT06349980 · 117 participants (planned) · Start Aug 5, 2024 · Primary completion Feb 10, 2027
Drug: HLX53 (1000mg); HLX53 (2000mg) and 2 more · For: Carcinoma, Hepatocellular
Sites: Shanghai, China
Shanghai Henlius BiotechIndustry
NCT05394168 · 12 participants · Start Dec 9, 2022 · Primary completion Dec 4, 2024
Drug: HLX53 · For: Advanced/Metastatic Solid Tumors
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Carcinoma, Hepatocellular
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.